Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

Omnicell OMCL is advancing toward the industry-defined vision of Autonomous Pharmacy by leveraging automation and advanced services across its cloud-based platform. The strength of the company’s ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to ...

The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

The VT Health Department, along with an Upper Valley nuring home is continuing to investigate the scoure of a Legionnaires’ outbreak.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...